The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
The US government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney ...
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...
The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.
The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.